Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach Read more about Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC Read more about Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma Read more about Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy Read more about Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy
A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer Read more about A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer
Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study Read more about Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study
Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach Read more about Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay Read more about Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay
Plasma first: Accelerating lung cancer diagnosis through liquid biopsy Read more about Plasma first: Accelerating lung cancer diagnosis through liquid biopsy